You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江健康(002435.SZ):奧美拉唑腸溶膠囊通過仿製藥一致性評價
格隆匯 03-09 16:44

格隆匯3月9日丨長江健康(002435.SZ)公佈,公司二級子公司海南海靈化學制藥有限公司(以下簡稱“海靈藥業”)於近日收到國家藥品監督管理局批准簽發的奧美拉唑腸溶膠囊的《藥品補充申請批件》,該藥品通過仿製藥質量和療效一致性評價。

奧美拉唑腸溶膠囊由阿斯利康研發,是第一個上市的質子泵抑制劑,臨牀用於胃、十二指腸潰瘍、反流性食管炎、卓-艾氏綜合徵的治療,於1988年在歐盟獲批上市,同年在中國上市,商品名為洛賽克。適應症:適用於胃潰瘍、十二指腸潰瘍、應激性潰瘍、反流性食管炎和卓-艾綜合徵(胃泌素瘤)。本品起效快,藥效強,在消化系統用藥方面極具競爭優勢。

據米內網數據統計,奧美拉唑腸溶膠囊2018年總體市場規模約為22億元。該藥品已被列入2019年版《國家基本醫療保險、工傷保險和生育保險藥品目錄》及《國家基本藥物目錄(2018年版)》,未來市場前景廣闊。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account